Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

Summary

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Timeline

Start

2025-10-15

Primary completion

2026-12-31

Completion

2028-12-31

Drugs

Indications